New Book Chapter from CEM on Microwave Peptide Synthesis
News Jun 17, 2013
CEM Corporation has announced its contribution of a new chapter on microwave peptide synthesis, which appears in Microwaves in Organic Synthesis, Volume 2, Third Edition, edited by Professor Antonio de la Hoz and Dr. André Loupy.
The chapter entitled, “Microwave-Enhanced Synthesis of Peptides, Proteins and Peptidomimetics,” was authored by Jonathan M. Collins, the initial developer of CEM’s microwave peptide synthesis technology, and offers an in-depth discussion of the theory, technology, and chemistry behind incorporating microwave energy into peptide synthesis with more than 300 cited references.
It provides a complete overview and analysis of all research to date in this field along with a mechanistic discussion of the common chemistries and side reactions encountered in solid phase peptide synthesis.
“This chapter is intended to be a useful tool for any researcher using or considering using microwave irradiation for solid phase synthesis of peptides and peptidomimetics” said Jonathan M. Collins, “The field is rapidly evolving and microwave has proven useful for reducing synthesis times as well as in many cases increasing peptide product purity.”
Collins, who holds degrees from the University of Florida, Northwestern University, and Stanford University, initiated CEM’s movement into microwave peptide synthesis in late 2002.
Currently, Director of Business Development for CEM Corporation, Collins continues to research microwave peptide synthesis and develop new methods and technologies to improve the process.
In 2013, CEM plans to announce several major developments in microwave peptide synthesis that will continue its leadership position in this field.
Protein's Role in Mitochondrial Metabolism IdentifiedNews
EXD2, a protein previously thought to be localised to the nucleus, has a key role in the production of proteins by mitochondria.READ MORE
Proteasome Blocker Brings Glaucoma Gene Therapy CloserNews
An enhanced gene therapy technique that pairs a viral vector with a proteasome blockade has doubled the therapy's efficiency.READ MORE